ArticleJournal of chemical information and modeling2025
ALLM-Ab: Active Learning-Driven Antibody Optimization Using Fine-Tuned Protein Language Models.
Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond affinity: AI-supported developability assessment and multi-objective optimization in antibody development.Antibody therapeutics · 2026Review
- Antibody-drug conjugate engineering: from design to efficacy and safety.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody engineering requires a delicate balance between enhancing binding affinity and maintaining developability properties. In this study, we present ALLM-Ab (Active Learning with Language Models for Antibodies), a novel active learning framework that leverages fine-tuned protein language models to accelerate antibody sequence optimization. By employing parameter-efficient fine-tuning via low-rank adaptation, coupled with a learning-to-rank strategy, ALLM-Ab accurately assesses mutant fitness while efficiently generating candidate sequences through direct sampling from the model's probability distribution. Furthermore, by integrating a multiobjective optimization scheme incorporating antibody developability metrics, the framework ensures that optimized sequences retain therapeutic antibody-like properties alongside improved binding affinity. We validate ALLM-Ab in both offline experiments using deep mutational scanning (DMS) data from the BindingGYM data set and online active learning trials targeting Flex ddG energy minimization across 15 antigens. Results demonstrate that ALLM-Ab not only expedites the discovery of high-affinity variants compared to baseline Gaussian process regression and genetic algorithm-based approaches, but also preserves critical antibody developability metrics. This work lays the foundation for more efficient and reliable antibody design strategies, with the potential to significantly reduce therapeutic development costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.